Over the last 7 days, the market has remained flat, but it is up 16% over the past year with earnings forecast to grow by 15% annually. In light of these conditions, identifying stocks with strong financials and a clear growth trajectory can be beneficial. While "penny stocks" might seem like an outdated term, they still represent smaller or less-established companies that could offer significant value.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ATRenew (RERE)	$4.68	$1.05B	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$2.14	$366.81M	✅ 3 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.34	$1.4B	✅ 5 ⚠️ 1 View Analysis >
FinVolution Group (FINV)	$4.89	$1.21B	✅ 4 ⚠️ 1 View Analysis >
Tuniu (TOUR)	$0.7625	$89.34M	✅ 2 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$183.07M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.52	$353.89M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$3.90	$792.06M	✅ 2 ⚠️ 2 View Analysis >
LifeVantage (LFVN)	$4.20	$55.32M	✅ 4 ⚠️ 3 View Analysis >

We'll examine a selection from our screener results.

Anavex Life Sciences (AVXL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anavex Life Sciences Corp. is a biopharmaceutical company with a market cap of $284.50 million.

Operations: Anavex Life Sciences Corp. currently does not report any revenue segments.

Market Cap: $284.5M

Anavex Life Sciences Corp., with a market cap of US$284.50 million, remains pre-revenue and debt-free, which is significant for a biopharmaceutical company focused on developing treatments for neurological conditions. Despite its unprofitability and volatile share price, Anavex has sufficient cash runway for over three years, providing financial stability as it advances its clinical development programs. Recent regulatory challenges include withdrawing an EU application for blarcamesine due to EMA feedback but continuing U.S. FDA engagements suggest ongoing commitment to Alzheimer's treatment development. The seasoned board and management team bolster confidence in navigating these complexities effectively.

Fossil Group (FOSL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Fossil Group, Inc. designs, develops, markets, and distributes consumer fashion accessories globally with a market cap of approximately $251.51 million.

Operations: The company's revenue is primarily derived from its operations in the Americas ($430.93 million), Europe ($333.25 million), and Asia ($238.65 million), with additional contributions from corporate activities ($1.58 million).

Market Cap: $251.51M

Fossil Group, Inc., with a market cap of US$251.51 million, faces challenges as it remains unprofitable and has seen increased losses over the past five years. Despite this, the company maintains sufficient short-term assets to cover both its short-term (US$301.8 million) and long-term liabilities (US$300.7 million). Recent earnings reports revealed a net loss of US$18.6 million for Q4 2025 on sales of US$280.5 million, down from the previous year’s figures. While management is relatively inexperienced with an average tenure of 1.2 years, Fossil's cash runway extends beyond three years if free cash flow reduction trends continue.

Weave Communications (WEAV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Weave Communications, Inc. provides an AI-powered platform for patient communications, engagement, and payments tailored for small and medium-sized healthcare businesses, with a market cap of $363.36 million.

Operations: The company generates revenue through its Weave Platform, amounting to $239.02 million.

Market Cap: $363.36M

Weave Communications, Inc., with a market cap of US$363.36 million, is navigating the penny stock landscape by focusing on its AI-powered platform for healthcare communications and payments. Despite being unprofitable, Weave has reduced its losses over the past five years and maintains a strong cash position with sufficient runway exceeding three years due to positive free cash flow. Recent board changes aim to enhance value creation through strategic oversight, while partnerships like those with Minted Technology Advisors and Synchrony bolster its service offerings. Revenue growth is projected at 12.81% annually, although profitability remains elusive in the near term.

Key Takeaways

• Reveal the 355 hidden gems among our US Penny Stocks screener with a single click here.
• Ready For A Different Approach? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.